TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC). Meeting Abstract

cited authors

  • Agarwal, Neeraj; Azad, Arun; Shore, Neal D.; Carles, Joan; Fay, Andre P.; Dunshee, Curtis; Karsh, Lawrence Ivan; Paccagnella, Maria Luisa; Di Santo, Nicola; Elmeliegy, Mohamed; Lin, Xun; Niyazov, Alexander; Czibere, Akos; Fizazi, Karim

Publication Date

  • May 20, 2021

webpage

published in

category

volume

  • 39

issue

  • 15